|
Conference/Events
| ShowHide Related Items >><< - 02/22/21
- NanoString announces launch of Whole Transcriptome Atlas
- 11/17/20
- NanoString, OHSU partner on GeoMx-based spatial profiling assays
- 09/09/20
- NanoString announces new GeoMx COVID-19 consortium
- $149.86 /
+12.12 (+8.80%) - 02/18/21
- Twist Bioscience and VCGS in development pact for diagnostic assay
- 02/03/21
- Twist Bioscience announces promotions including Siyuan Chen as CTO
- 01/19/21
- Twist Bioscience enters two licensing agreements with Serotiny, Applied StemCell
- 01/14/21
- Twist Bioscience begins shipping new synthetic RNA reference controls
- 02/24/21
- Children's Mercy Kansas City implements four PacBio Sequel IIe Systems
- 02/18/21
- Pacific Biosciences announces LabCorp's addition of PacBio Sequel II Systems
- 02/10/21
- Pacific Biosciences reports Q4 EPS 40c, consensus 32c
- 02/10/21
- Pacific Biosciences announces $900M investment from SoftBank
- 02/24/21
- Qiagen, Inovio expand collaboration to develop NGS companion diagnostic
- 02/16/21
- Paulson & Co. buys Exxon, exits Qiagen in Q4
- 02/10/21
- Qiagen CEO says will consider potential 'bolt-on acquisitions'
- 02/09/21
- Quidel CEO tells Bloomberg won't enter deal without 'obvious strategic fit'
- 02/16/21
- Third Point buys Upstart, exits Caesars in Q4
- 10/05/20
- 10x Genomics acquires ReadCoor for $350M
- 09/15/20
- 10x Genomics shipping Chromium Single Cell Multiome ATAC + Gene Expression
- 01/13/21
- Codexis, Tate & Lyle expand relationship to enhance stevia, allulose production
- 02/23/21
- PerkinElmer launches point of care Covid-19 antigen test for mass screening
- 02/22/21
- PerkinElmer gives update on Valencia Branch Laboratory's accreditation process
- 02/16/21
- Organogenesis appoints David Francisco as CFO
- 01/14/21
- PerkinElmer SARS-CoV-2 RT-PCR assay receives FDA EUA for asymptomatic testing
- 02/19/21
- Illumina, University Hospital of Tubingen to evaluate WGS potential
- 02/08/21
- Illumina accelerator invests in nine genomics startups for second global cycle
- 02/04/21
- Illumina announces agreement with Belgian Society of Medical Oncology
- 01/20/21
- Illumina wins patent infringement suit against BGI in U.K.
- 02/26/21
- Regeneron announces CHMP recommendation for COVID-19 antibody cocktail
- 02/24/21
- Prothena announces presentation of new preclinical PRX005 data
- 02/19/21
- Atea Pharmaceuticals announces Chugai in-license of AT-527 from Roche
- 02/12/21
- Genentech announces results from four Phase III studies of faricimab
- 02/22/21
- Bionano Genomics announces publication on genome-wide model
- 02/11/21
- Bionano Genomics announces publication on method for optical genome mapping
- 02/09/21
- Bionano Genomics' Saphyr adopted by Canada's largest hospital diagnostic lab
- 02/02/21
- Bionano Genomics announces publication of study on DNA methylation
- 01/11/21 Baird
- NanoString price target raised to $70 from $60 at Baird
- 01/06/21 Cowen
- NanoString upgraded to Outperform with $75 target at Cowen
- 01/06/21 Cowen
- NanoString upgraded to Outperform from Market Perform at Cowen
- 12/02/20 JPMorgan
- NanoString price target raised to $60 from $45 at JPMorgan
- $149.86 /
+12.12 (+8.80%) - 02/05/21 Baird
- Twist Bioscience price target raised to $200 from $125 at Baird
- 02/05/21 JPMorgan
- Twist Bioscience downgraded to Underweight from Neutral at JPMorgan
- 01/04/21 Evercore ISI
- Evercore ISI cuts Twist Bioscience to In Line, says new verticals take time
- 01/04/21 Evercore ISI
- Twist Bioscience downgraded to In Line from Outperform at Evercore ISI
- 02/11/21 Cantor Fitzgerald
- Pacific Biosciences price target raised to $62 from $45 at Cantor Fitzgerald
- 02/11/21 Piper Sandler
- Pacific Biosciences upgraded to Overweight from Neutral at Piper Sandler
- 01/15/21 Piper Sandler
- Pacific Biosciences price target raised to $20 from $12 at Piper Sandler
- 01/12/21 Cantor Fitzgerald
- Pacific Biosciences price target raised to $45 from $25 at Cantor Fitzgerald
- 02/19/21 Berenberg
- Qiagen price target raised to EUR 56 from EUR 52 at Berenberg
- 02/09/21 William Blair
- Quidel, Qiagen merger would not make sense, says William Blair
- 02/09/21 Wells Fargo
- Qiagen shares should be sold on latest merger talk, says Wells Fargo
- 02/09/21 Citi
- Merger with Qiagen would benefit Quidel, says Citi
- 02/18/21 Cowen
- 10x Genomics price target raised to $200 from $155 at Cowen
- 02/18/21 JPMorgan
- 10x Genomics price target raised to $195 from $160 at JPMorgan
- 02/18/21 Citi
- 10x Genomics price target raised to $240 from $195 at Citi
- 12/16/20 Citi
- 10x Genomics price target raised to $195 from $165 at Citi
- 06:53 Today Stifel
- Codexis initiated with a Buy at Stifel
- 12/30/20 Benchmark
- Codexis price target raised to $29 from $21 at Benchmark
- 07/15/20 Stephens
- Codexis resumed with an Overweight at Stephens
- 03/10/20 Benchmark
- Codexis initiated with a Buy at Benchmark
- 02/03/21 Citi
- PerkinElmer price target raised to $155 from $150 at Citi
- 01/07/21 Piper Sandler
- Oxford Immunotec downgraded to Neutral from Overweight at Piper Sandler
- 01/07/21 Wells Fargo
- PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo
- 01/07/21 Wells Fargo
- PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo
- 02/16/21 BTIG
- Illumina price target raised to $570 from $410 at BTIG
- 02/12/21 Piper Sandler
- Illumina price target raised to $510 from $415 at Piper Sandler
- 02/12/21 Cowen
- Illumina price target raised to $460 from $385 at Cowen
- 12/22/20
- Fly Intel: Top five analyst upgrades
- 02/25/21 Berenberg
- Roche price target lowered to CHF 320 from CHF 325 at Berenberg
- 02/24/21 Morgan Stanley
- Roche price target lowered to CHF 345 from CHF 365 at Morgan Stanley
- 02/23/21 BofA
- BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
- 02/17/21 UBS
- UBS downgrades Roche to Neutral on risk to 2022 estimates
- 02/08/21 Oppenheimer
- Bionano Genomics price target raised to $15 from $1.50 at Oppenheimer
- 01/26/21 Ladenburg
- Bionano Genomics price target raised to $14 from $1.25 at Ladenburg
- 01/22/21 Maxim
- Bionano Genomics price target raised to $14 from $2 at Maxim
- 12/04/20 Roth Capital
- Bionano Genomics downgraded to Neutral from Buy at Roth Capital
- 01/10/21
- NanoString sees Q4 product/service revenue $35.7M, consensus $33.36M
- 11/09/20
- NanoString reports Q3 EPS (56c), consensus (60c)
- 10/06/20
- NanoString sees Q3 product/service revenue $30.1M, consensus $27.19M
- $149.86 /
+12.12 (+8.80%) - 02/04/21
- Twist Bioscience backs FY21 revenue view $110M-$118M, consensus $116.02M
- 02/04/21
- Twist Bioscience reports Q1 EPS (72c), consensus (74c)
- 11/23/20
- Twist Bioscience sees Q1 revenue $25M-$26M
- 11/23/20
- Twist Bioscience sees FY21 revenue $110M-$118M, consensus $117.9M
- 01/11/21
- Pacific Biosciences sees Q4 revenue $27M, consensus $23.69M
- 11/02/20
- Pacific Biosciences reports Q3 EPS (14c), consensus (13c)
- 02/09/21
- Qiagen backs FY21 EPS view $2.42-$2.46, consensus $2.40
- 02/09/21
- Qiagen reports Q4 EPS 68c, consensus 65c
- 12/08/20
- Qiagen sees FY21 adj. EPS $2.42-$2.46 CER, consensus $2.40
- 12/08/20
- Qiagen raises FY20 adj. EPS view to $2.13-$2.14 CER from $2.07-$2.09 CER
- 02/17/21
- 10x Genomics sees FY21 revenue $480M-$500M, consensus $494.02M
- 02/17/21
- 10x Genomics reports Q4 EPS ($3.87), consensus (23c)
- 11/10/20
- 10x Genomics reports Q3 EPS (65c), consensus (30c)
- 02/25/21
- Codexis sees FY21 revenue $82M-$85M, consensus $80.53M
- 02/25/21
- Codexis reports Q4 EPS (6c), consensus (12c)
- 11/05/20
- Codexis reports Q3 EPS (10c), consensus (11c)
- 02/02/21
- PerkinElmer sees Q1 adjusted EPS of at least $3.00, consensus $2.40
- 02/02/21
- PerkinElmer sees FY21 adjusted EPS at least $8.50, consensus $8.88
- 02/02/21
- PerkinElmer reports Q4 adjusted EPS $3.96, consensus $3.00
- 01/11/21
- PerkinElmer sees Q4 adjusted EPS 'at least' $3.60, consensus $2.79
- 02/11/21
- Illumina sees FY21 adjusted EPS $5.10-$5.35, consensus $6.11
- 02/11/21
- Illumina reports Q4 adjusted EPS $1.22, consensus $1.11
- 02/11/21
- Notable companies reporting after market close
- 01/11/21
- Illumina sees FY21 adjusted EPS $5.10-$5.35, consensus $6.61
- 02/04/21
- Roche reports 2020 core EPS CHF 19.16 vs. CHF 20.16 last year
- 10/27/20
- Oncolytics announces new GI cancer study using
- 10/15/20
- Roche confirms outlook for 2020 based on assessment of COVID-19
- 10/15/20
- Roche reports 9 months group sales CHF43.98B vs. CHF46.07B last year
- 11/12/20
- Bionano Genomics reports Q3 revenue $2.2M, consensus $2.07M.
- 10/15/20
- Bionano Genomics sees Q3 revenue $1.9M-$2.3M, consensus $2.07M
|
|
Downgrade
| ShowHide Related Items >><< - $32.45 /
-26.68 (-45.12%) - 10/29/20
- Ontrak acquires behavior change platform LifeDojo
- 10/13/20
- Ontrak rises after announcing launch of Ontrak-CI program
- 02/24/21
- CVS Health to administer COVID-19 vaccines in six additional states
- 02/18/21
- Capital Senior Living completes first round of COVID-19 vaccinations
- 02/16/21
- CVS has capacity to administer 20M-25M Covid vaccines per month
- 02/16/21
- CVS Health sees Q1 as lowest earnings quarter for the year
- $32.45 /
-26.68 (-45.12%) - 10:17 Today RBC Capital
- Ontrak downgraded to Sector Perform from Outperform at RBC Capital
- 01/05/21 Benchmark
- GM, Roku, Marcus among Benchmark's Best Ideas for first half of 2021
- 01/04/21 B. Riley Securities
- Ontrak price target raised to $110 from $100 at B. Riley Securities
- 11/18/20 B. Riley Securities
- Ontrak initiated with a Buy at B. Riley Securities
- 01/29/21 Jefferies
- Carvana, Walmart among 13 additions to Jefferies Franchise Picks list
- 01/22/21 Baird
- Tabula Rasa HealthCare may have lost MTM deal at Aetna, says Baird
- 01/19/21 JPMorgan
- Teladoc remains top 2021 healthcare technology pick at JPMorgan
- 01/08/21
- Fly Intel: Top five analyst upgrades
- $32.45 /
-26.68 (-45.12%) - 08:07 Today
- Ontrak sees FY21 revenue $100M, consensus $165.05M
- 08:06 Today
- Ontrak reports Q4 EPS (7c), consensus (30c)
- 11/05/20
- Ontrak reports Q3 EPS (36c), consensus (35c)
- 02/16/21
- CVS Health sees FY21 revenue $276.1B-$280.6B, consensus $278.39B
- 02/16/21
- CVS Health sees FY21 adjusted EPS $7.39-$7.55, consensus $7.54
- 02/16/21
- CVS Health reports Q4 adjusted EPS $1.30, consensus $1.24
- 11/06/20
- CVS Health raises FY20 adj. EPS view to $7.35-$7.45 from $7.14-$7.27
- 02/14/21
- Walmart COVID vaccine rollout heading to small towns, WSJ reports
- 02/11/21
- CVS, Walmart to decide who gets leftover vaccine doses, WSJ reports
- 01/02/21
- Coca-Cola, Disney among value stocks deserving a fresh look, Barron's says
- 12/20/20
- CDC panel says frontline workers, people over 74 should be next, NYTimes reports
- 02/16/21
- Fly Intel: Wall Street's top stories at midday
- 02/16/21
- Fly Intel: Pre-market Movers
- 12/01/20
- Fly Intel: What to watch in Salesforce's earnings report
- 11/17/20
- Fly Intel: Wall Street's top stories at midday
- $32.45 /
-26.68 (-45.12%) - 10/12/20
- Largest borrow rate increases among liquid names
- 09/16/20
- Ontrak put volume heavy and directionally bearish
- 09/15/20
- Ontrak put volume heavy and directionally bearish
- 02/16/21
- Unusually active option classes on open February 16th
- 01/11/21
- CVS Health call volume above normal and directionally bullish
- 11/17/20
- Unusually active option classes on open November 17th
- 11/10/20
- CVS Health call volume above normal and directionally bullish
|
|
Recommendations
| ShowHide Related Items >><< - 07:50 Today
- Homology Medicines regains worldwide rights to ophthalmology program
- 02/08/21
- Homology reports first presentation of data from IND-enabling studies of HMI-203
- 01/12/21
- Pfizer invests $120M in four clinical-stage biotech companies
- 01/06/21
- Homology Medicines announces plans for three clinical programs in 2021
- 07:50 Today
- Homology Medicines regains worldwide rights to ophthalmology program
- 02/17/21
- Novartis announces SCD grant agreement with Bill & Melinda Gates Foundation
- 02/16/21
- Novartis reports Entresto granted expanded indication in chronic heart failure
- 02/11/21
- Novartis' Sandoz agrees to acquire GSK's cephalosporin antibiotics business
- 12/14/20 H.C. Wainwright
- Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
- 11/08/20 Oppenheimer
- Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
- 08/11/20 Oppenheimer
- Homology Medicines price target lowered to $27 from $32 at Oppenheimer
- 08/11/20 H.C. Wainwright
- Homology Medicines price target lowered to $30 from $37 at H.C. Wainwright
- 02/02/21 Morgan Stanley
- Novartis price target lowered to CHF 102 from CHF 104 at Morgan Stanley
- 02/01/21 Truist
- iRhythm price target lowered to $220 from $265 at Truist
- 02/01/21 Cowen
- Novartis downgraded to Market Perform after 'tepid' guidance at Cowen
- 02/01/21 Cowen
- Novartis downgraded to Market Perform from Outperform at Cowen
- 11/09/20
- Homology Medicines reports Q 3EPS (62c), consensus (80c)
- 01/26/21
- Novartis sees 2021 core operating income to grow mid single digit
- 01/26/21
- Novartis reports Q4 core EPS $1.34, consensus $1.36
- 11/05/20
- Xoma reports Q3 EPS (10c), consensus (21c)
- 10/27/20
- Novartis raises FY20 core operating income growth outlook
- 12/23/20
- Judge rules against White House drug pricing rule, Reuters says
- 11/23/20
- EU seeks easier access to generic medicines, Reuters says
- 11/20/20
- Trump to release new rules aimed at lowering drug prices, WSJ reports
- 11/19/20
- Fly Intel: After-Hours Movers
- 02/11/21
- Fly Intel: Wall Street's top stories for Thursday
- 02/11/21
- Fly Intel: Wall Street's top stories at midday
- 02/11/21
- Fly Intel: Pre-market Movers
- 12/26/20
- Week in review: How Trump's policies moved stocks
|
|
Technical Analysis
| ShowHide Related Items >><< $NSD NASDAQ Market Internals - 02/26/21
- NASDAQ market internals summary
- 02/26/21
- NASDAQ market internals summary
- 02/26/21
- NASDAQ market internals summary
- 02/26/21
- NASDAQ market internals summary
|
|
Downgrade
|
RBC Capital analyst Sean… ShowHide Related Items >><< - $32.50 /
-26.63 (-45.04%) - 10/29/20
- Ontrak acquires behavior change platform LifeDojo
- 10/13/20
- Ontrak rises after announcing launch of Ontrak-CI program
- $32.50 /
-26.63 (-45.04%) - 01/05/21 Benchmark
- GM, Roku, Marcus among Benchmark's Best Ideas for first half of 2021
- 01/04/21 B. Riley Securities
- Ontrak price target raised to $110 from $100 at B. Riley Securities
- 11/18/20 B. Riley Securities
- Ontrak initiated with a Buy at B. Riley Securities
- 10/02/20 Canaccord
- Ontrak analysis points to significant upside for shares, says Canaccord
- $32.50 /
-26.63 (-45.04%) - 08:07 Today
- Ontrak sees FY21 revenue $100M, consensus $165.05M
- 08:06 Today
- Ontrak reports Q4 EPS (7c), consensus (30c)
- 11/05/20
- Ontrak reports Q3 EPS (36c), consensus (35c)
- $32.50 /
-26.63 (-45.04%) - 10/12/20
- Largest borrow rate increases among liquid names
- 09/16/20
- Ontrak put volume heavy and directionally bearish
- 09/15/20
- Ontrak put volume heavy and directionally bearish
|